HK Stock Market Move | ANTENGENE-B(06996) tail rise by more than 5%, the company plans to increase investment in AI drug research and development, XeVio new indications previously included in medical insurance.

ANTENGENE-B (06996) rose more than 5% in the final trading session, with a cumulative increase of 180% within the month. At the time of the report, it was up 4.69% at 2.23 Hong Kong dollars, with a turnover of 1425.96 million Hong Kong dollars. On the news front, on February 19, Deqi Pharmaceuticals announced plans to increase investment to establish a dedicated AI department by integrating resources. This initiative includes locally deploying DeepSeek to accelerate the development of the T-cell engager (TCE) platform with spatial hindrance shielding effects. By integrating existing resources over the past four years and locally deploying DeepSeek, the company will use specific algorithms and AI data collection to integrate and analyze cross-database multi-omics information. This approach can effectively sort and select candidate proteins, identify new tumor antigens suitable for TCE, and accelerate the company's TCE platform's pipeline development. Debon Securities pointed out that Shivo's sales revenue in the first half of 2024 was 60.8 million yuan, and in July 2024, after being approved for the first time for the treatment of relapsed or refractory multiple myeloma (R/RMM), it was approved for a second indication in China for the treatment of R/RDLBCL. Shivo's two approved indications in China have been included in the national medical insurance catalog, further expanding the coverage of medical insurance. It is worth mentioning that Shivo achieved a "triple jump" from approval, listing, to inclusion in medical insurance within six months.